Adrienne P Borschuk1, Robin S Everhart2, Michelle N Eakin3, Devin Rand-Giovannetti4, Belinda Borrelli5, Kristin A Riekert6. 1. Department of Psychology, Virginia Commonwealth University, P.O. Box 842018, Richmond, VA 23284-2018, United States. Electronic address: apborschuk@vcu.edu. 2. Department of Psychology, Virginia Commonwealth University, P.O. Box 842018, Richmond, VA 23284-2018, United States. Electronic address: reverhart@vcu.edu. 3. Division of Pulmonary and Critical Care Medicine, Johns Hopkins Adherence Research Center, Johns Hopkins School of Medicine, United States. Electronic address: meakin1@jhmi.edu. 4. Division of Pulmonary and Critical Care Medicine, Johns Hopkins Adherence Research Center, Johns Hopkins School of Medicine, United States. Electronic address: drandgio@gmail.com. 5. Department of Health Policy & Health Services Research, Boston University, 560 Harrison Avenue, Boston, MA 02118, United States. Electronic address: belindab@bu.edu. 6. Division of Pulmonary and Critical Care Medicine, Johns Hopkins Adherence Research Center, Johns Hopkins School of Medicine, United States. Electronic address: riekert@jhmi.edu.
Abstract
BACKGROUND: This study aimed to quantify cystic fibrosis (CF) disclosure and examine associations between disclosure and psychosocial and health outcomes. METHODS: Participants completed measures assessing disease disclosure and psychosocial outcomes. Data from chart reviews and pharmacy records were obtained. RESULTS: Participants (N=128; ages 16-63) were more likely to disclose to romantic partners (97%) and close friends (94%) than to casual friends (79%), bosses (71%), or co-workers (53%). Participants reported more comfort discussing CF with and doing treatments in front of romantic partners and close friends than other groups. Disclosure was associated with higher social support, social functioning, and medication adherence self-efficacy. Lower lung-function was associated with disclosure to bosses and co-workers. CONCLUSIONS: Clinicians should consider discussing disclosure with patients, as limited disclosure may have a negative impact on psychosocial outcomes.
BACKGROUND: This study aimed to quantify cystic fibrosis (CF) disclosure and examine associations between disclosure and psychosocial and health outcomes. METHODS:Participants completed measures assessing disease disclosure and psychosocial outcomes. Data from chart reviews and pharmacy records were obtained. RESULTS:Participants (N=128; ages 16-63) were more likely to disclose to romantic partners (97%) and close friends (94%) than to casual friends (79%), bosses (71%), or co-workers (53%). Participants reported more comfort discussing CF with and doing treatments in front of romantic partners and close friends than other groups. Disclosure was associated with higher social support, social functioning, and medication adherence self-efficacy. Lower lung-function was associated with disclosure to bosses and co-workers. CONCLUSIONS: Clinicians should consider discussing disclosure with patients, as limited disclosure may have a negative impact on psychosocial outcomes.
Authors: Christina J Nicolais; Ruth Bernstein; Estefany Saez-Flores; Katherine A McLean; Kristin A Riekert; Alexandra L Quittner Journal: J Clin Psychol Med Settings Date: 2019-12